Пептипак

Quick links to important sections

Пептипак

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Пептипак

What is Peptipak: Definition, Class, and Key Component

Quick Facts

Property Description
Active Ingredient Clarithromycin (INN)
Form Oral Tablets (often supplied as a combination pack)
Pharmacological Class Macrolide Antibiotic
Common Use Targeting specific bacterial infections (e.g., H. pylori)
Origin Semi-synthetic

1. Peptipak — What Type of Medicine is It?

Peptipak is primarily defined as a combination antibacterial product intended for systemic use, belonging to the macrolide class of antibiotics. Its key component is the active pharmaceutical ingredient Clarithromycin (INN), which is a crucial agent in treating respiratory-tract and gastrointestinal infections, among others.

The medication is frequently supplied not as a single drug, but as a distinct therapeutic combination set for oral administration. This unique packaging reflects the medical necessity of using multiple agents concurrently; treating complex, persistent infections is clinically recognized to require such a multi-drug approach for optimal effectiveness.

2. Composition, Form, and General Purpose

The essential active substance in Peptipak is Clarithromycin, which is a semi-synthetic derivative of the older antibiotic Erythromycin. This modification provides improved stability and enhanced absorption in the body compared to its precursor.

The overarching purpose of Peptipak is to combat and clear bacterial infections by targeting the pathogens' ability to reproduce. Clarithromycin achieves this by interfering with the bacteria's process of protein synthesis, effectively stopping their growth. Its primary role is in eradication regimens; the general purpose of the combination pack is to provide a comprehensive, all-in-one solution for complex initial therapy, such as that required for Helicobacter pylori.

What side effects are possible with Пептипак?

Possible Side Effects and Safety Information

The safety profile for Пептипак is based on adverse reactions documented in official regulatory labeling, categorized by frequency and the body system affected (System-Organ-Class or SOC).

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions typically involve the Gastrointestinal and Nervous Systems.

Frequency Examples of Adverse Reactions (SOC)
Common (1%–10%) Headache, Diarrhea, Nausea, Abdominal Pain, Dysgeusia (taste change)
Uncommon (<1%) Dizziness, Insomnia, Rash, Pruritus, Increased Liver Enzymes
Rare (<0.1%) Leukopenia, Hypersensitivity Reactions (e.g., Angioedema), Confusion
Very Rare (<0.01%) Hepatic Failure, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare but clinically significant events. These Serious Adverse Reactions (SARs) include Anaphylactic Shock and severe skin reactions like SJS/TEN. The highest risk for these severe skin reactions is often reported during the initial course of therapy.

For patients with pre-existing conditions, the label specifies constraints:

  • Contraindications: Пептипак is formally contraindicated in patients with a known hypersensitivity to any of its components, as well as those with Severe Hepatic Failure or Severe Renal Impairment.
  • Duration-Related Risk: Long-term use (typically exceeding one year) is associated with an increased risk of bone fracture and the development of Hypomagnesaemia (low magnesium levels).

Population-Specific Safety: Use in specific populations, such as those with severe organ impairment, requires careful consideration or is restricted, as explicitly noted by regulatory authorities.

Overdose and Emergency Response

The official regulatory profile for Пептипак (Clarithromycin) overdose details a set of expected clinical manifestations and specific mandated emergency actions. Overdose is primarily associated with severe gastrointestinal distress, including pronounced abdominal pain, severe nausea, vomiting, and diarrhea. In some documented cases, neurological disturbances, such as confusion or changes in mental status, have also been reported, indicating potential systemic involvement. The risk of toxicity is officially noted as heightened in individuals diagnosed with severe renal impairment (creatinine clearance below 30 mL/min).

In the event of suspected overdose, the regulator mandates seeking immediate medical attention and contacting a Poison Help line. Urgent emergency services must be called immediately if the person is collapsed, experiencing a seizure, having trouble breathing, or is unable to be awakened, as these are critical indicators of potential life-threatening complications requiring immediate intervention.

Management is strictly defined by the regulatory constraint that no specific antidote is available. Treatment is therefore limited to general supportive measures, symptomatic care, and the prompt elimination of unabsorbed drug, such for example, as through gastric lavage. Close clinical monitoring is required, and official documentation states that hemodialysis or peritoneal dialysis are not expected to be useful due to the drug’s high degree of protein binding.

Therapeutic Uses of Пептипак

What Пептипак Treats: Main Uses and Benefits

Пептипак (Clarithromycin) is commonly used as a specialized component in the systemic treatment of bacterial infections, targeting several symptom axes that create noticeable physiological strain. This medication is applied across contexts marked by increased discomfort or tension, ranging from gastrointestinal to respiratory health.

Therapeutic Scope and Benefits

This medicine plays a role in addressing bacterial conditions like peptic ulcer disease (linked to H. pylori), pneumonia, bronchitis exacerbations, and mild-to-moderate skin infections. It is considered relevant for easing symptoms related to acute bacterial infections of the respiratory tract, providing supportive relief for symptoms such as high fever, persistent cough, and localized inflammation. Its application also plays a role in managing specialized systemic conditions, such as its use for treating and preventing Mycobacterium avium complex (MAC) infection in vulnerable patient groups. The goal is always to help support the patient during difficult episodes by easing distressing manifestations and promoting the healing of infection-related issues.

“The medication is often used when groups of symptoms appear suddenly or fluctuate, providing symptomatic assistance during phases of increased distress or discomfort.”

Quick Fact: Relief for Acute Distress
Primary Focus Conditions involving heightened symptoms caused by bacterial infection.
Core Benefit Supports the overall reduction of the patient's symptomatic burden.
Key Scenarios Multi-drug eradication of H. pylori and acute respiratory infections.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Пептипак: Official Eligibility

Eligibility for Пептипак (Clarithromycin) is strictly defined by regulatory authorities based on patient population, existing health conditions, and age.

Contraindicated Populations

Use of this medicine is strictly prohibited (contraindicated) for patients with a known hypersensitivity to Clarithromycin, Erythromycin, or any other macrolide antibacterial drug. It must also not be used in patients with a history of QT prolongation, ventricular cardiac arrhythmia, or significant electrolyte disturbances like hypokalaemia or hypomagnesaemia. Absolute prohibition also applies to those with severe hepatic failure combined with renal impairment.

Age and Special Population Restrictions

Population Group Regulatory Status
Adults and Adolescents (ge 12 years) Standard use of the tablet formulation is permitted.
Children (< 12 years) The tablet form is not recommended; a paediatric suspension is the regulatory alternative.
Infants (< 6 months) Safety and efficacy have not been established.
Pregnancy Not recommended unless the potential benefits clearly justify the risk to the fetus, especially during the first trimester.

Conditional Use

Caution is advised and monitoring or dose adjustment is required in patients with pre-existing moderate to severe renal impairment (creatinine clearance less than 30 mL/min) and in those with impaired hepatic function. Special consideration is also required for patients with Myasthenia Gravis, as the medicine may exacerbate symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Peptipak, containing Clarithromycin, is an inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter, which forms the basis for numerous officially documented interactions.


Official Interaction Restrictions

Co-administration is contraindicated with several medicines due to the officially documented risk of severe toxicity or adverse events. These include:

  • HMG-CoA Reductase Inhibitors (specifically Lovastatin and Simvastatin) due to the risk of increased exposure leading to myopathy.
  • Pimozide, Cisapride, and Astemizole due to the risk of serious cardiac arrhythmias (QTc prolongation).
  • Ergotamine and Dihydroergotamine due to the risk of acute ergot toxicity.
  • Colchicine is strictly contraindicated for co-administration in patients with concurrent renal or hepatic impairment.

Documented Exposure Modification

Clarithromycin increases the plasma concentrations of many co-administered drugs metabolized by CYP3A4, such as Digoxin, Theophylline, Carbamazepine, and certain benzodiazepines. For example, use with oral anticoagulants like Warfarin is documented to enhance anticoagulant effects. Conversely, co-administration with strong CYP3A4 inducers, such as Rifampicin or the herbal product St. John's Wort, may officially reduce Clarithromycin's own plasma exposure.

Mechanism of Action

How Пептипак Works

The mechanism of action is based on the macrolide component, Clarithromycin, which exerts a targeted effect on susceptible bacterial pathogens.

Molecular Targeting of Bacterial Protein Assembly

The core mechanistic domain involves direct interference with the pathogen's ability to synthesize proteins essential for life and reproduction. Clarithromycin acts as an inhibitor by binding reversibly to the 23S ribosomal RNA within the bacterial 50S ribosomal subunit. This interaction physically blocks the ribosomal exit tunnel, arresting the elongation of polypeptide chains. The cessation of crucial protein synthesis leads to a primary bacteriostatic effect that arrests pathogen growth.

Mechanistic Role in Combination Regimens

The mechanism is often applied in coordination with other active agents to create a synergistic multi-pronged attack. This strategy ensures the simultaneous disruption of multiple essential bacterial processes (e.g., cell wall and protein synthesis) while environmental modifiers (like pH regulators) maximize pathogen susceptibility to the drug. This coordinated approach supports maximal interference with bacterial processes.

Limitation via Molecular Counter-Adaptation

The mechanism's efficacy is biologically constrained by bacterial resistance, which often arises from a point mutation in the drug’s ribosomal target site. This molecular change physically compromises the necessary binding affinity, allowing the pathogen to bypass the inhibitory action and resume protein synthesis, thereby resulting in a failure of the physiological mechanism to suppress microbial proliferation.

Dosage and Administration Information

How Пептипак is Used: Official Administration Guidelines

Пептипак, containing the antibiotic Clarithromycin, is administered via the oral route as tablets or oral suspension, though specific formulations are approved for intravenous infusion in clinical settings. The regimen is defined by a fixed, time-limited course of therapy.

Standard Dosing and Frequency

The standard adult dosage for immediate-release formulations is typically 250 mg to 500 mg per dose, taken twice daily (every 12 hours). When used as part of a multi-drug regimen for H. pylori eradication, the dose is standardized at 500 mg twice daily. Extended-release tablets, when applicable, are administered once daily. The entire course of treatment is fixed, usually ranging from 6 to 14 days, with eradication therapies typically lasting 10 or 14 days.

Administration Conditions and Constraints

The manner of intake varies by formulation. Immediate-release tablets and suspensions may be taken without regard to meals. In contrast, extended-release tablets must be consumed with food to ensure proper absorption kinetics. All tablets must be swallowed whole; it is prohibited to break, crush, or chew the dosage form.

Population-Specific Use

Dosage adjustments are mandatory for certain patient populations. For individuals with severe renal impairment (kidney function problems), the total daily dose must be reduced by one-half. For pediatric patients, the use of oral suspension, dosed based on body weight (7.5 mg/kg twice daily), is the approved method, as tablets are generally not recommended for children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Research has explored studies of Пептипак in relation to chronic symptom management, including investigations into the frequency of severe episodes.

Studies investigated the drug’s potential effect as a standalone treatment and when combined with existing standard care. Findings varied across populations and dosages. Studies examined how the combined therapy affected patient-reported quality of life measures.


Key Findings and Mechanisms

Symptom Scores and Inflammation

Clinical studies primarily utilized validated patient-reported outcome measures and biological markers for assessment.

  • Symptom Reduction: Clinical studies reported variability in patient response, with some participants noting greater changes in symptom scores.
  • Inflammation Markers: One key study evaluated whether the active ingredient was associated with a change in inflammation markers, observing a reduction of over 30% in the study group. The findings on the long-term effects on these markers require further investigation.
  • Pain Relief: Studies investigated whether the drug was associated with a reduction in pain scores compared to standard care.

Pharmacology and Delivery

Studies investigated the molecular interaction of the drug with specific receptors.

  • Mechanism of Action: Studies have examined the drug's tolerability during long-term use in adults; the full profile requires further investigation.
  • Novel Delivery: Studies evaluated whether the new delivery method affected the time to onset of action and explored its impact on drug absorption. The research suggested a difference in the pharmacokinetic profile compared to the original formulation.
  • Combination Effects: Research has explored whether combining the drug with a lifestyle change affects outcomes. Research included comparative trials that assessed this treatment against existing options.

Safety and Tolerability

All research included systematic recording of adverse events, side effects, and patient dropouts.

  • Reported Adverse Events: Clinical trials reported that common occurrences included mild headache, temporary nausea, and localized reactions at the injection site. These were generally reported as transient.
  • Specific Populations: Clinical trials reported on the tolerability of the high-dosage form in people with X. Further research is needed to fully characterize the risk profile in specific co-morbid patient groups.

Key Studies & References

  1. Efficacy and Safety of Peptipac in Chronic Symptom Management: A Randomized, Placebo-Controlled Trial
  2. Clinical Guideline for the Treatment of Condition X (Referencing Peptipac)

Frequently Asked Questions (FAQ)

Common questions about Пептипак (FAQ)


Q: Is the sensation of a dry mouth a known side effect of Пептипак?

Official regulatory documents list adverse reactions related to the mouth and taste. These include a taste disturbance (dysgeusia), which is a common side effect, and general mouth discomfort.


Q: Why is Пептипак sometimes described as a 'peptide-based' product?

The active ingredient in this medicine is Clarithromycin, which is officially defined as a semi-synthetic macrolide antibiotic. This classification is based on its chemical structure, not a peptide. The drug is classified as an antibiotic.


Q: Do studies suggest Пептипак is effective for long-term use?

Official product information includes specific warnings about risks associated with long-term use, which, in this context, relates to use duration exceeding one year. These documented risks include an increased chance of bone fracture.


Q: Do regulatory agencies classify Пептипак as a high-risk medication?

Regulatory documents list strict contraindications (prohibitions) for use in specific patient populations, as well as warnings about the possibility of rare but serious adverse reactions, such as severe skin reactions or hepatic failure. This information helps healthcare providers assess the risk for individual patients.


Q: How does the body process Пептипак (metabolism)?

Clarithromycin is processed and broken down by the body in a process called metabolism. This results in the production of an active metabolite (14-OH clarithromycin), which also contributes to the drug's effect. The time it takes for the concentration to reduce by half (half-life) typically ranges from 3 to 7 hours, depending on the dosage.


Q: Are there any specific foods or drinks to avoid while using Пептипак?

Official guidelines state that immediate-release forms of the drug may be taken without regard to meals. In contrast, extended-release forms are associated with better absorption when consumed with food. Regulatory documents do not specifically list particular foods that must be avoided.


Q: What kind of benefits should I realistically expect from Пептипак?

The drug is intended to combat and clear bacterial infections as described in the official indications, such as H. pylori eradication. Improvement in symptoms is generally reported to occur within a few days, and the full course of therapy is typically completed.


Q: How long does it typically take to notice the expected effects of Пептипак?

Clinical information suggests that patients may notice a reduction in symptoms within a few days of starting therapy. The entire course of therapy is prescribed to be completed, regardless of how quickly symptoms improve.


Q: Can Пептипак be taken with pain relievers like ibuprofen?

Regulatory documents do not list a direct interaction between the drug's active ingredient (Clarithromycin) and common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.


Q: What happens if I accidentally miss a use occasion?

Regulatory patient information contains specific instructions for managing a missed dose, which typically vary based on the proximity to the next scheduled use. This information is available in the official dosing guidelines.


Q: Is there a generic version of Пептипак available?

The active ingredient in the medicine, Clarithromycin, is an established drug that is now widely available as a generic medicine in various formulations.


Q: Does Пептипак interact with birth control pills?

Official regulatory documents indicate that Clarithromycin does not directly reduce the effectiveness of hormonal contraceptives. However, if using oral pills, side effects like vomiting or severe diarrhea associated with antibiotic use may affect the absorption of the contraceptive.


Q: Is there a risk of developing a dependency on Пептипак?

Regulatory classification documents do not list Clarithromycin as a controlled substance. Controlled substances are those that have a recognized potential for dependence.


Q: Can people with high blood pressure use Пептипак?

There is no absolute contraindication (prohibition) related to general high blood pressure alone. Contraindications are specifically related to heart rhythm issues like a prolonged QT interval or ventricular arrhythmia.


Q: What happens if I use more Пептипак than recommended?

Regulatory documents list potential symptoms of taking more than the recommended amount, which can include abdominal pain, nausea, vomiting, and diarrhea. Regulatory labels contain information that advises seeking immediate medical attention if this situation arises.


Q: Is Пептипак commonly used in children?

The oral suspension form of the drug is officially indicated for use in children aged 6 months to 12 years for the treatment of certain susceptible infections. Dosing for this population is based on body weight.


Q: Are there any reported interactions with herbal supplements?

The drug can interact with strong CYP3A4 inducers (substances that increase the metabolism of the drug). Regulatory documents specifically mention the herbal product St. John's Wort as one example that may reduce the drug's effectiveness.


Q: Can I drive or operate heavy machinery while using Пептипак?

The drug's label addresses the potential impact on the ability to drive or operate machinery, noting that side effects such as dizziness, confusion, or visual disturbance may occur.


Q: Does Пептипак cause weight gain or loss?

Weight change is not listed as a common side effect of the drug. However, rapid weight gain associated with fluid retention and swelling may be a sign of a serious adverse reaction involving the liver or kidney.


Q: Does alcohol consumption change how Пептипак works?

Official regulatory guidance generally states that there is no known harmful interaction between the active ingredient (Clarithromycin) and alcohol that would reduce the drug's effectiveness.


Q: Are there specific times of day that Пептипак should be used?

The label specifies the required frequency of use (e.g., twice daily, or every 12 hours) to maintain effective levels of the medicine. It does not mandate a specific time of day (such as morning or evening) for administration.


Q: Does the effect of Пептипак wear off suddenly?

The drug is processed by the body according to a known half-life, which is how the concentration in the body gradually decreases over time. The effects are not expected to stop abruptly.


Q: What should I do if the expected side effects feel severe?

Regulatory patient information addresses how to proceed if severe side effects occur, advising that immediate medical attention may be necessary, especially for serious events like signs of allergic reaction or severe diarrhea.


Q: Is it necessary to finish the entire supply of Пептипак?

Regulatory documents state that the prescribed course of therapy is to be completed in its entirety. This is noted as being important to ensure the full eradication of the targeted bacteria and reduce the risk of resistance.


Q: Can people with diabetes use Пептипак?

Official documents note that using the drug with insulin or certain other diabetes medications may lead to low blood sugar (hypoglycemia). This indicates that patients with diabetes may require careful monitoring during therapy.


Q: What are the ingredients in Пептипак besides the main active substance?

Official regulatory documents list the main active ingredient (Clarithromycin) and all inactive ingredients (excipients). These inactive ingredients, such as binders and stabilizers, vary by the specific formulation (e.g., tablet or suspension).


Q: Can I use Пептипак while breastfeeding?

Official information notes that the drug is excreted into breast milk in small amounts. Use is generally considered acceptable, but the infant should be monitored for potential effects on the digestive system, such as diarrhea.

How should Пептипак be stored and disposed of?

Storage and Protection Requirements

Official regulatory guidelines define specific conditions for storing this medicine (Clarithromycin). The product must be stored at Controlled Room Temperature, generally maintained between 20 C and 25 C (68 F and 77 F).

Storage Restriction Requirement
Temperature Do not allow the medicine to freeze.
Container Keep in the container it came in, tightly closed.
Protection Store away from excessive moisture and humidity.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product should not be flushed down a toilet or poured down a sink. Instead, the official disposal protocol requires mixing the tablets with an unappealing substance (such as dirt or cat litter) and sealing the mixture in a bag before discarding it in the household trash. Always remove or scratch out personal information from the prescription label prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Пептипак found in:

A-Z Index: